Key Takeaways for Johnson & Johnson Stock as of July 2026
- TREMFYA Breakout: TREMFYA cleared $2B in quarterly sales for the first time, up 71% YoY on 58% induction share in ulcerative colitis.
- TIKR Target: $336 is where TIKR’s mid-case model pins Johnson & Johnson stock by December 2030, a 28% total return from today’s $263 price, or 6% annualized over 4.4 years.
- Analyst Split: Twenty-two analysts cover Johnson & Johnson stock, split 11 buy, 5 outperform, 6 hold and 1 sell, with a mean target of $271.
- Drawdown Recovery: Johnson & Johnson stock now sits just 1.44% below its recent peak.
TREMFYA’s First $2 Billion Quarter Forces Johnson & Johnson to Raise Guidance
Johnson & Johnson (JNJ) turned in a $2 billion quarter for TREMFYA in the three months ended June 2026, the first time the drug has cleared that mark, and sales grew 71% year over year. That number did more to move the July 15 earnings call than any other line item, because it confirmed TREMFYA is replacing the revenue STELARA is losing to biosimilar competition, and doing it faster than the guidance implied. Innovative Medicine sales overall reached $16.4 billion, up 6.8%, despite a 760 basis point drag from STELARA baked directly into that number.
STELARA sales fell 55.7% in the quarter, a 460 basis point drag on total reported growth. TREMFYA’s advance in inflammatory bowel disease more than offset it. Worldwide Chairman of Innovative Medicine Jennifer Taubert told analysts on the call that in ulcerative colitis, TREMFYA holds “58% share of induction for the IL-23s,” adding the drug also leads new patient starts in Crohn’s disease. That share position, built within 18 months of the drug’s IBD approval, is why management raised full-year 2026 operational sales growth guidance to 6.5% to 7.1% and lifted adjusted EPS guidance to $11.50 to $11.65, an $0.18 increase at the midpoint. Excluding STELARA entirely, the rest of the Innovative Medicine business grew more than 14%, a figure that tells the real story behind the raise.
The market has treated the quarter as a beat and moved on. But TREMFYA’s number is not a one-off. New FUZION study data, showing TREMFYA as the only IL-23 inhibitor effective in perianal fistulizing Crohn’s disease, a segment covering roughly a quarter of Crohn’s patients, points to more share capture ahead. That is the development repricing Johnson & Johnson stock: a franchise transition once expected to be a multiyear drag has become the company’s fastest grower, and guidance is only now catching up to it.
That trend shows up on the balance sheet too: operating income grew 8% year over year to $7.24 billion as margin recovered to 29%, evidence the operating leverage behind Johnson & Johnson’s Q2 beat is building right alongside TREMFYA’s share gains.
Johnson & Johnson Stock Claws Back From a 10.96% Drawdown as Wall Street Stays Bullish
JNJ stock hit its steepest drawdown of the past year on May 8, 2026, falling 11% from its high as STELARA’s biosimilar losses and Abiomed’s slowdown weighed on sentiment.
The stock has since clawed back nearly all of that decline and now trades just 1.44% below its recent peak. That recovery lines up with TREMFYA’s acceleration through the second quarter, evidence the market is starting to price in the STELARA-to-TREMFYA handoff rather than just the STELARA decline.
Twenty-two analysts cover Johnson & Johnson stock, split between 11 buy ratings, 5 outperforms, 6 holds, 1 sell and 1 no opinion.
The mean target sits at $271, just 3% above the current $263 price, with estimates ranging from a low of $190 to a high of $305. That mean target has climbed steadily from $169 a year ago to $271 today, tracking the same TREMFYA-driven earnings momentum behind the July guidance raise, and the range between the high and low estimate has widened as analysts debate how much credit the STELARA-to-TREMFYA handoff deserves.
TIKR Values Johnson & Johnson Stock at $336, Pricing In TREMFYA’s Takeover
TIKR’s mid-case model values Johnson & Johnson stock at $336 by December 2030, a 28% total return from the current price of $263, or 6% annualized over 4.4 years.
A 6% annualized return positions Johnson & Johnson stock closer to a steady healthcare compounder than a growth story, the kind of return investors accept from a diversified drugmaker trading near its highs rather than demand from a single-drug bet.
That target is reachable because TREMFYA’s IBD share gains are still early, with FUZION data opening a new segment of Crohn’s patients and management already raising guidance once this year. The model is pricing a franchise transition that the market spent 2025 treating as a headwind, and the second quarter is the first hard evidence that the transition is now a tailwind instead.
Should You Invest in Johnson & Johnson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up JNJ stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Johnson & Johnson alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JNJ stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
